Treatment of tumors with miRNA targeting CDK4/CDK6
Summary
USPTO granted patent US12595483B2 to the Institute for Cancer Research of Fox Chase Cancer Center for miRNA mimics targeting CDK4 and/or CDK6 for tumor treatment, including colon cancer. The patent covers modified oligonucleotides comprising miRNA and methods for administering the compositions to patients.
What changed
USPTO has granted patent US12595483B2 to the Institute for Cancer Research of Fox Chase Cancer Center covering miRNA mimics targeting CDK4 and/or CDK6 for tumor treatment. The patent includes 4 claims on modified oligonucleotides and treatment methods for cancers including colon cancer.
This grant establishes intellectual property rights that may influence R&D investment decisions and competitive positioning in the miRNA-based cancer therapy space. Entities developing similar miRNA therapeutics targeting CDK4/CDK6 pathways should consider potential licensing needs or design-around strategies.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Treatment of tumors with miRNA targeting CDK4/CDK6
Grant US12595483B2 Kind: B2 Apr 07, 2026
Assignee
INSTITUTE FOR CANCER RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER
Inventors
Amriti R. Lulla, Wafik S. El-Deiry
Abstract
The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
CPC Classifications
C12N 15/113 C12N 2310/141
Filing Date
2023-11-16
Application No.
18510877
Claims
4
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.